Trial Profile
A Phase IIa Trial of NP-178 (Emoxipin) for the Treatment of Inflammatory Bowel Disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2018
Price :
$35
*
At a glance
- Drugs Emoxipin (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 29 Nov 2018 New trial record
- 13 Nov 2018 According to a Nash Pharmaceuticals media release, the company plan to present preclinical in vivo IBD results at an upcoming conference and will update the market on plans for this phase IIa study for the leading repurposed IBD candidate NP-178 in 2019 pending additional results shortly.